1. Home
  2. NVNI vs STTK Comparison

NVNI vs STTK Comparison

Compare NVNI & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVNI
  • STTK
  • Stock Information
  • Founded
  • NVNI 2019
  • STTK 2016
  • Country
  • NVNI Brazil
  • STTK United States
  • Employees
  • NVNI N/A
  • STTK N/A
  • Industry
  • NVNI
  • STTK Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVNI
  • STTK Health Care
  • Exchange
  • NVNI Nasdaq
  • STTK Nasdaq
  • Market Cap
  • NVNI 31.5M
  • STTK 37.6M
  • IPO Year
  • NVNI N/A
  • STTK 2020
  • Fundamental
  • Price
  • NVNI $0.35
  • STTK $0.83
  • Analyst Decision
  • NVNI
  • STTK Hold
  • Analyst Count
  • NVNI 0
  • STTK 4
  • Target Price
  • NVNI N/A
  • STTK $3.00
  • AVG Volume (30 Days)
  • NVNI 1.3M
  • STTK 423.3K
  • Earning Date
  • NVNI 08-07-2025
  • STTK 07-31-2025
  • Dividend Yield
  • NVNI N/A
  • STTK N/A
  • EPS Growth
  • NVNI N/A
  • STTK N/A
  • EPS
  • NVNI N/A
  • STTK N/A
  • Revenue
  • NVNI $31,250,627.00
  • STTK $4,606,000.00
  • Revenue This Year
  • NVNI $12.05
  • STTK N/A
  • Revenue Next Year
  • NVNI $15.02
  • STTK N/A
  • P/E Ratio
  • NVNI N/A
  • STTK N/A
  • Revenue Growth
  • NVNI 1491.58
  • STTK 69.65
  • 52 Week Low
  • NVNI $0.14
  • STTK $0.69
  • 52 Week High
  • NVNI $12.19
  • STTK $4.99
  • Technical
  • Relative Strength Index (RSI)
  • NVNI 53.38
  • STTK 38.86
  • Support Level
  • NVNI $0.28
  • STTK $0.75
  • Resistance Level
  • NVNI $0.38
  • STTK $0.85
  • Average True Range (ATR)
  • NVNI 0.03
  • STTK 0.09
  • MACD
  • NVNI 0.01
  • STTK -0.01
  • Stochastic Oscillator
  • NVNI 74.21
  • STTK 9.59

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: